Again, we have a different research group publishing news about the recent ILC studies that have been performed here in the US using TCGA data as well as in Europe with the METABRIC data.

UNC researcher, Gatza, reported early research at the 2014 SABCS, as pointed out in this thread: "BC genomic analysis reveals invasive lobular carcinoma subtypes".

Also, Belgium-based Christine Desmedt and Christos Sotiriou summarized the European METABRIC ILC data last month here:
"Genomic Characterization of Primary Invasive Lobular Breast Cancer"

This latest news release, released yesterday in the JCO, has a nice summary in the final paragraph, which states:
"Desmedt et al,2 in concert with similar initiatives published within the past few months,3 have extensively characterized the genomic landscape of ILC and have produced remarkably consistent results that identify at least three significantly altered and therapeutically relevant pathways. These are an important first step to understanding ILC as well as the potential treatment implications of this unique biologic subset of breast cancer. It is now clear that ILC and IDC are distinct molecular diseases, a fact that should be considered in future experimental and therapeutic initiatives."

Great!

Who in the breast cancer industry has the leadership skills to organize and launch ILC clinical trials that exploit some of these ILC mutations?
This research, while wonderful, won't change guidelines in the clinic unless trials are launched.